Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer in first human trial
Disease control
Recruiting now
This early-phase trial is testing a new radioactive drug called FL-020 in 50 men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to seek out and deliver radiati…
Phase: PHASE1 • Sponsor: Full-Life Technologies UK Limited • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC